Deciphera Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DECIPHERA PHARMS, and when can generic versions of DECIPHERA PHARMS drugs launch?
DECIPHERA PHARMS has one approved drug.
There are thirty-five US patents protecting DECIPHERA PHARMS drugs.
There are eighty-one patent family members on DECIPHERA PHARMS drugs in twenty-three countries.
Summary for Deciphera Pharms
| International Patents: | 81 |
| US Patents: | 35 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Deciphera Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,779,572 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,850,241 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 8,461,179 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 8,188,113 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
